Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients

Fig. 2

Prognostic value of the ROS scoring system in TCGA dataset. a A Kaplan-Meier analysis of overall survival (OS) for ovarian cancer patients in TCGA dataset with the ROS scoring system (high [scores 13–25], the green line v.s. low [scores 0–12], the blue line) is shown (P < 0.001, respectively, log-rank test). b A Kaplan-Meier analysis of overall survival (OS) for advanced stage (stage III/ IV) ovarian cancer patients in TCGA dataset with the ROS scoring system is shown (P < 0.001, respectively, log-rank test). c A Kaplan-Meier analysis of overall survival (OS) for advanced stage (stage III/ IV) ovarian cancer patients received a platinum and taxane regimen as first-line chemotherapy in TCGA dataset with the ROS scoring system is shown (P < 0.001, respectively, log-rank test). All statistical tests were two-sided.

Back to article page